Spirea welcomes Dr Bo Rode Hansen as Executive Director as the company further strengthens its management and business capabilities
Cambridge, UK, 4th November 2024: Spirea Limited, a biopharmaceutical company developing a new generation of antibody drug conjugate (ADC) cancer therapeutics, based on its unique multivalent ELIVATE linker technology, is delighted to announce the appointment of Dr Bo Rode Hansen as an Executive Director. Bo will lead Spirea to secure the company’s primary position in […]